LegalView Reveals Details of the FDA Mandated Black Box Warning For Fluoroquinolone Antibiotics Such as Cipro and Levaquin
July 14, 2008 (PRLEAP.COM) Health NewsDenver, CO - LegalView reported details of a recent U.S. Food and Drug Administration (FDA) mandate regarding the fluoroquinolones antibiotics family of drugs. All of the fluoroquinolones will now carry black box warning labels to ensure physicians and patients understand that the drugs have been associated with an increased risk of tendonitis and tendon rupture.
Among the most common of the fluoroquinolone antibiotics are Levaquin, Cipro, Factive and Avelox - some of the most commonly prescribed anti-bacterial drugs. Levaquin, also known as levofloxacin, is an antibiotic that fights infections including bronchitis, pneumonia, Chlamydia, gonorrhea, skin infections, urinary tract infections, etc. A study released in The Journal of American Board of Family Medicine reported the Levaquin warning and associated risks with prescribing the drug, however, the drug was approved for the use of children as an antibiotic and potential treatment for airborne anthrax in 2008 only a few years after the report was published. Individuals who have taken Levaquin are advised to contact an experienced pharmaceutical attorney to learn about the potential for developing a Levaquin lawsuit.
Cipro is manufactured and sold by Bayer A.G. and is used to treat bacterial infections, although it is not recommended for victims of the common cold or flu. A study published in the Clinical Rheumatology December 2003 issue, noted the relationship of the drug's consumption compared to patients with Achilles' tendon rupture and reported that there may be cause for a Cipro warning that links the drug's use to the risk of tendonitis. In addition to this risk, other Cipro side effects can include seizure, difficulty breathing, hallucinations, depression, blacking out, chest pain, suicidal thoughts and numbness.
Factive is an oral prescription drug that has also been linked to the tendon rupture as the most serious risk, although some other Factive side effects can be considered just as serious, including phototoxicity, abnormal heartbeats and central nervous system conditions. The drug was released for market in April 2003 from Oscient Pharmaceuticals with the tendonitis Factive warning printed on an informational pamphlet issued by the company, although it was not at that time marketed with a black box warning even though the risks of Achilles' tendon rupture were known among the manufacturers. Factive, similar to Cipro and Levaquin, treats lung bacterial infections for patients 18 years and older.
Finally, adult patients who have been taking Avelox (moxifloxacin HCL) for treatment of either bacterial sinusitis, bronchitis or pneumonia infections should be aware that an Avelox warning and increase of a black box labeling will also be issued per the FDA's mandate. Because Avelox is part of the fluoroquinolones antibiotic group, the Avelox side effects also consists of an increased risk for tendonitis or tendon tear/rupture.
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView.